A team of Russian scientists from Moscow Institute of Physics and technology (MIPT), Institute of organic chemistry (RAS), Institute of Development Biology (RAS) and the Institute of Biophysics (RAS) proposed new drugs with cancer in which there are compounds derived from the seeds of parsley and dill.
Results of the research have been published in the Journal of Natural Products.
Currently the main method of treating cancer is chemotherapy. Treatment uses anti-fungal agents that inhibit the growth of cancer cells by tearing the process of mitosis (i.e. cell division). Cancer cells are divided into cancer much more quickly than in normal cells, and thus are more likely to anty-moo-chroming measures.
For example, the number of melanoma cells doubles every 3 days, and the amount of their healthy progenitor cells melanocytes is increased by 15%, and even when cell division is stimulated. Microtubules play an important role in the process of mitosis.
They are composed of proteins called tubulin. Tubulin binding, anti-fungal measures affect the dynamics of micro-tubules and are interfering with cell cycle, which stops the cells from dividing and then selective death.
Study focuses on a strong middle anty-mitotic balvanized-single list of the Brazilian tree
The synthesis of these preparations is quite labor intensive, requires costly substances involved in the reactions necessary to obtain the final product, and catalysts to speed up chemical reactions. The authors proposed a new and more efficient process of linking glazing, consisting of six stages. Precursors of this phenomenon are the seeds from the plants, especially parsley and fennel.
In addition to glazing, there are still a number of other structural equivalents subject to synthesize to help you find similarities with favorable properties of the anty-mitotic. Anti-tumor activity was investigated using two independent methods of using embryos of sea urchins and human cancer cells. In order to further confirm the anti-cancer effect of active molecules, they were testing various human cancer cells, such as lung cancer, melanoma, prostate, breast, colon and ovarian cancer.
Experience has shown that the test to be effective in reducing the growth of melanoma cells, and non-toxic for healthy blood cells, used as control. Future plans include both optimization of compound to improve its metabolic stability and solubility, and studies of human cells in mice to confirm the anti-cancer and clinical development potential.